References
- Bonilla, F. A. and Geha, R. S. 2006. Update on primary immunodeficiency diseases. J. Allergy Clin. Immunol. 117:S435–441.
- Burleson, G. R. and Burleson, F. G. 2008. Testing human biologicals in animal host resistance models. J. Immunotoxicol. 5:23–31.
- Chapman, K., Pullen, N., Graham, M., andRagan, I. 2007. Nonclinical safety testing of monoclonal antibodies: the significance of species relevance. Nature Rev./Drug Discov. 6:120–126.
- CHMP (Committee for Medicinal Products for Human Use). 2007. Guideline on strategies to identify and mitigate risks for first-in-man clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367.
- ESG (Expert Scientific Group) on Phase One Clinical Trials: Final report (Norwich, US: Stationery Office, 2006. http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAnd Guidance/DH_063117.
- HESI Immunotoxicology Technical Committee, Clinical Immuno toxicology Workshop, Meeting Minutes, February, 2005. http://www.hesiglobal.org/NR/rdonlyres/18E51EC7-BFEC-4799-AA30-87FBE57D8D23/0/AttachmentG.doc.
- ICH (International Conference on Harmonization). 2000. Guidance for Industry. M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals.
- ICH (International Conference on Harmonization). 2006. Guidance for Industry. S8 Immunotoxicity Studies for Human Pharmaceuticals.
- Mohan, V. P., Scanga, C. A., Keming, Y., Scott, H. M., Tanaka, K. E., Tsang, E., Tsai, M. C., Flynn, J. L., and Chan, J. 2001. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role of limiting pathology. Infect. Immun. 69:1847–1855.
- O’Brien, D. P., Briles, D. E., Szalai, A. J., Tu, A. H., Sanz, I., and Nahm, M. H. 1999. Tumor necrosis factor-α receptor I is important for survival from Streptococcus pneumoniae infections. Infect. Immun. 67:595–601.
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., and Panoskaltsis, N. 2006. Cytokine storm in a Phase 1 trial of anti-CD28 monoclonal antibody TGN1412. New Engl. J. Med. 355:1018–1028.
- Treacy, G. 2000. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFα monoclonal antibody. Hum. Exp. Toxicol. 19: 226–228.
- Weaver, J. L., Tsutsui, N., Hisada, S., Vidal, J.-M., Spanhaak, S., Sawada, J., Hastings, K. L., van der Laan J.W., van Loveren H., Kawabata, T.T., Sims, J., Durham, S. K., Fueki, O., Matula, T. I., Kusunoki, H., Ulrich, P., and Nakamura, K. 2005. Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices. J. Immunotoxicol. 2:171–180.
- Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E. W., Jäger, H. R., and Clifford, D. B. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl. J. Med. 354:924–933.